MD Anderson researchers studied vudalimab, also known as XmAb20717, as a potential immunotherapy option for advanced rare cancers, including pleural and peritoneal mesothelioma. This video explains why researchers were interested in a single-agent approach that targets both PD-1 and CTLA-4, and how clinical trials may shape the future of mesothelioma treatment.
If you or a loved one has been diagnosed with mesothelioma after asbestos exposure, learn more at asbestosclaims.law.
Read more on this
Talk with an asbestos lawyer
If something in this video sounds like your family's story, start with what you remember, and we'll take it from there.
More videos like this
This page is provided for general informational purposes and does not constitute legal advice. Every asbestos case turns on its own facts, exposure history, diagnosis, deadlines, available evidence, and applicable law. Reviewing this page does not create an attorney-client relationship. For advice about your specific situation, call 833-4-ASBESTOS for a free case review.